Greylock XIV GP LLC sold $97M of FIG
owner at Figma, Inc.. 3,074,755 shares at an average of $31.52, traded Aug 1, 2025, filed Aug 5, 2025.
Score components
- +12Role10% owner
- +25Trade size$96.9M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster11 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -31.0%, 3m -42.1%, 6m -73.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-103347, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 1, 2025 | CConversion Class A Common Stockindirect: By Greylock XIV-A Limited Partnership | +3,035,825 | - | - | 3,074,767 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Class A Common Stockindirect: By Greylock XIV Limited Partnership | +54,644,628 | - | - | 55,345,586 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Class A Common Stockindirect: By Greylock XIV Principals LLC | +3,035,825 | - | - | 3,074,767 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Class A Common Stockindirect: By Greylock XIV-A Limited Partnership | -153,738 | $31.52 | $4.8M | 2,921,029 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Class A Common Stockindirect: By Greylock XIV Limited Partnership | -2,767,279 | $31.52 | $87M | 52,578,307 | Aug 5, 2025 |
| Aug 1, 2025 | SOpen-market sale Class A Common Stockindirect: By Greylock XIV Principals LLC | -153,738 | $31.52 | $4.8M | 2,921,029 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -715 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -12,861 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series Seed Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -715 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series A Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -2,061,065 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series A Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -37,099,101 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series A Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -2,061,065 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series B Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -633,180 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series B Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -11,397,150 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series B Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -633,180 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -282,261 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -5,080,658 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series C Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -282,261 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series D Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -20,570 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series D Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -370,245 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series D Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -20,570 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series E Preferred Stockderivativeindirect: By Greylock XIV-A Limited Partnership | -38,034 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series E Preferred Stockderivativeindirect: By Greylock XIV Limited Partnership | -684,613 | $0.00 | $0 | 0 | Aug 5, 2025 |
| Aug 1, 2025 | CConversion Series E Preferred Stockderivativeindirect: By Greylock XIV Principals LLC | -38,034 | $0.00 | $0 | 0 | Aug 5, 2025 |
Related signals
Other insiders at Figma, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 8Weak | Figma, Inc. | Tyler Herb Chief Accounting Officer | $31k 1,418 shares | -1% | |
| 20Weak | Figma, Inc. | Brendan Mulligan General Counsel and Secretary | $450k 20,701 shares | -3% | |
| 9Weak | Figma, Inc. | Tyler Herb Chief Accounting Officer | $37k 1,416 shares | -1% | |
| 33Weak | Figma, Inc. | Brendan Mulligan General Counsel and Secretary | $2.8M 109,106 shares | -15% | |
| 33Weak | Figma, Inc. | Brendan Mulligan General Counsel and Secretary | $6.3M 211,599 shares | -23% | |
| 10Weak | Figma, Inc. | Tyler Herb Chief Accounting Officer | $60k 2,000 shares | -1% | |
| 17Weak | Figma, Inc. | Tyler Herb Chief Accounting Officer | $50k 1,840 shares | -1% | |
| 41Moderate | Figma, Inc. | Index Ventures VI (Jersey) LP owner | $317k 12,475 shares | -2% | |
| 44Moderate | Figma, Inc. | Daniel H. Rimer director | $317k 12,475 shares | -2% | |
| 10Weak | Figma, Inc. | Tyler Herb Chief Accounting Officer | $18k 709 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.